The CRI is a protein kinase inhibitor, used for the treatment of variety of cancers like non-small cell lung carcinoma . The order of compatibility was found to be i.e. pBuOzi > pPrOzi ≈ pPentOx > pBuOx (Figure ). The formulation results showed A-pBuOx-A to be the best solubilizer for CRI (≈ 1.15 g/L at 2 g/L feed) (LC ≈ 10 wt.% and LE ≈ 57%) (Figure ), which according to Ra calculation should be the least efficient in solubilizing CRI. The inhouse CRI aqueous solubility was found to be 0.08 g/L (Table ). No increase in solubility was observed with the further increase in CRI feed. At CRI feed of 4 to 10 g/L, A-pPentOx-A and A-pBuOzi-A, being structural isomers, exhibited similar solubilizing capacity i.e. ≈ 0.6 to 0.8 g/L.